Performance of FDG PET/CT in the clinical management of breast cancer

In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art positron emission tomography (PET)/computed tomography (CT) technology. The strengths and limitations of FDG PET/...

Full description

Saved in:
Bibliographic Details
Published in:Radiology Vol. 266; no. 2; p. 388
Main Authors: Groheux, David, Espié, Marc, Giacchetti, Sylvie, Hindié, Elif
Format: Journal Article
Language:English
Published: United States 01.02.2013
Subjects:
ISSN:1527-1315, 1527-1315
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art positron emission tomography (PET)/computed tomography (CT) technology. The strengths and limitations of FDG PET/CT are examined in various clinical settings, and the following questions are answered: Is FDG PET/CT useful to differentiate malignant from benign breast lesions? Can FDG PET/CT replace sentinel node biopsy for axillary staging? What is the role of FDG PET/CT in initial staging of inflammatory or locally advanced breast cancer? What is the role of FDG PET/CT in initial staging of clinical stage IIA and IIB and primary operable stage IIIA breast cancer? How does FDG PET/CT compare with conventional techniques in the restaging of cancer in patients who are suspected of having disease recurrence? What is the role of FDG PET/CT in the assessment of early response to neoadjuvant therapy and of response to therapy for metastatic disease? Some recommendations for clinical practice are given.
AbstractList In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art positron emission tomography (PET)/computed tomography (CT) technology. The strengths and limitations of FDG PET/CT are examined in various clinical settings, and the following questions are answered: Is FDG PET/CT useful to differentiate malignant from benign breast lesions? Can FDG PET/CT replace sentinel node biopsy for axillary staging? What is the role of FDG PET/CT in initial staging of inflammatory or locally advanced breast cancer? What is the role of FDG PET/CT in initial staging of clinical stage IIA and IIB and primary operable stage IIIA breast cancer? How does FDG PET/CT compare with conventional techniques in the restaging of cancer in patients who are suspected of having disease recurrence? What is the role of FDG PET/CT in the assessment of early response to neoadjuvant therapy and of response to therapy for metastatic disease? Some recommendations for clinical practice are given.In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art positron emission tomography (PET)/computed tomography (CT) technology. The strengths and limitations of FDG PET/CT are examined in various clinical settings, and the following questions are answered: Is FDG PET/CT useful to differentiate malignant from benign breast lesions? Can FDG PET/CT replace sentinel node biopsy for axillary staging? What is the role of FDG PET/CT in initial staging of inflammatory or locally advanced breast cancer? What is the role of FDG PET/CT in initial staging of clinical stage IIA and IIB and primary operable stage IIIA breast cancer? How does FDG PET/CT compare with conventional techniques in the restaging of cancer in patients who are suspected of having disease recurrence? What is the role of FDG PET/CT in the assessment of early response to neoadjuvant therapy and of response to therapy for metastatic disease? Some recommendations for clinical practice are given.
In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art positron emission tomography (PET)/computed tomography (CT) technology. The strengths and limitations of FDG PET/CT are examined in various clinical settings, and the following questions are answered: Is FDG PET/CT useful to differentiate malignant from benign breast lesions? Can FDG PET/CT replace sentinel node biopsy for axillary staging? What is the role of FDG PET/CT in initial staging of inflammatory or locally advanced breast cancer? What is the role of FDG PET/CT in initial staging of clinical stage IIA and IIB and primary operable stage IIIA breast cancer? How does FDG PET/CT compare with conventional techniques in the restaging of cancer in patients who are suspected of having disease recurrence? What is the role of FDG PET/CT in the assessment of early response to neoadjuvant therapy and of response to therapy for metastatic disease? Some recommendations for clinical practice are given.
Author Hindié, Elif
Giacchetti, Sylvie
Groheux, David
Espié, Marc
Author_xml – sequence: 1
  givenname: David
  surname: Groheux
  fullname: Groheux, David
  email: dgroheux@yahoo.fr
  organization: Department of Nuclear Medicine and Department of Medical Oncology, Breast Diseases Unit, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France. dgroheux@yahoo.fr
– sequence: 2
  givenname: Marc
  surname: Espié
  fullname: Espié, Marc
– sequence: 3
  givenname: Sylvie
  surname: Giacchetti
  fullname: Giacchetti, Sylvie
– sequence: 4
  givenname: Elif
  surname: Hindié
  fullname: Hindié, Elif
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23220901$$D View this record in MEDLINE/PubMed
BookMark eNpNjztPwzAUhS1URB8wsyGPLGl9r-NHR1TaglSJDmWOHOcGghKnOOnAv28risR0zvB9RzpjNghtIMbuQUwBUjuLrqjaegoIIKySV2wECk0CEtTgXx-ycdd9CQGpsuaGDVEiirmAEVtuKZZtbFzwxNuSr57XfLvczRY7XgXefxL3dRUq72p-YtwHNRT6M5hHcl3P_VmMt-y6dHVHd5ecsPfVcrd4STZv69fF0ybxUss-Qcpp7qVXKSrvzbx0JSqnPRTG5iiM9Zq08s5pLaBEQExdoVOtTSmV1Q4n7PF3dx_b7wN1fdZUnae6doHaQ5cBWokG9MmcsIcLesgbKrJ9rBoXf7K_63gEI35bYg
CitedBy_id crossref_primary_10_1007_s13139_016_0437_6
crossref_primary_10_4103_ijnm_ijnm_183_22
crossref_primary_10_1016_j_jacr_2023_02_016
crossref_primary_10_1016_j_anl_2020_01_002
crossref_primary_10_1016_j_ejrad_2020_108975
crossref_primary_10_1088_2057_1976_1_1_015202
crossref_primary_10_1016_j_pec_2015_02_012
crossref_primary_10_12998_wjcc_v12_i11_1885
crossref_primary_10_1007_s12282_015_0613_z
crossref_primary_10_1016_j_ejrnm_2014_07_006
crossref_primary_10_1186_s13058_025_02087_6
crossref_primary_10_1016_j_jacr_2022_02_010
crossref_primary_10_4103_ijmr_IJMR_1368_16
crossref_primary_10_1007_s11605_013_2291_5
crossref_primary_10_1016_j_bulcan_2025_02_014
crossref_primary_10_2217_nnm_2018_0168
crossref_primary_10_1007_s12149_018_1307_3
crossref_primary_10_1093_jjco_hyad032
crossref_primary_10_1186_s12880_018_0254_8
crossref_primary_10_1002_cplu_202400095
crossref_primary_10_1016_j_nima_2015_10_071
crossref_primary_10_3390_biomedicines10030667
crossref_primary_10_1007_s00259_024_06866_9
crossref_primary_10_1088_1361_6560_aaa44c
crossref_primary_10_1007_s00259_016_3402_9
crossref_primary_10_3389_fonc_2023_1149791
crossref_primary_10_1016_j_cpet_2023_12_002
crossref_primary_10_1186_s40644_020_00325_y
crossref_primary_10_3390_diagnostics11111954
crossref_primary_10_1016_j_mpsur_2015_10_004
crossref_primary_10_1093_jncimonographs_lgv013
crossref_primary_10_1097_RCT_0000000000001020
crossref_primary_10_1007_s12149_018_1259_7
crossref_primary_10_1016_j_gynor_2013_06_003
crossref_primary_10_1371_journal_pone_0176782
crossref_primary_10_1038_s41598_020_78865_3
crossref_primary_10_1007_s00259_014_2941_1
crossref_primary_10_4103_ijc_IJC_1202_20
crossref_primary_10_1038_s41598_024_78383_6
crossref_primary_10_1016_j_jacr_2017_08_037
crossref_primary_10_1186_s13550_018_0466_5
crossref_primary_10_1007_s00259_019_4259_5
crossref_primary_10_1016_j_radphyschem_2018_01_019
crossref_primary_10_1186_1471_2407_14_272
crossref_primary_10_1371_journal_pone_0094017
crossref_primary_10_5306_wjco_v5_i5_982
crossref_primary_10_1007_s12282_016_0685_4
crossref_primary_10_1007_s10549_014_3072_x
crossref_primary_10_1097_MNM_0000000000000928
crossref_primary_10_1016_j_acra_2015_02_012
crossref_primary_10_1097_MNM_0000000000000768
crossref_primary_10_1684_bdc_2013_1847
crossref_primary_10_1002_hep_26781
crossref_primary_10_1007_s00259_025_07460_3
crossref_primary_10_3892_etm_2024_12788
crossref_primary_10_1007_s12149_019_01364_7
crossref_primary_10_1097_MNM_0000000000001610
crossref_primary_10_1016_j_ejrad_2014_05_037
crossref_primary_10_1007_s00259_017_3705_5
crossref_primary_10_1007_s00259_017_3709_1
crossref_primary_10_1016_j_mednuc_2019_10_002
crossref_primary_10_1016_j_mednuc_2014_05_004
crossref_primary_10_1016_j_mednuc_2014_05_005
crossref_primary_10_1097_RLU_0000000000004491
crossref_primary_10_1016_j_clinimag_2017_06_001
crossref_primary_10_1016_j_breastdis_2016_01_019
crossref_primary_10_1245_s10434_015_4403_9
crossref_primary_10_1007_s11604_020_00966_w
crossref_primary_10_1007_s12253_019_00641_0
crossref_primary_10_1038_s41598_017_01524_7
crossref_primary_10_3389_fonc_2022_1007874
crossref_primary_10_1007_s00259_024_06696_9
crossref_primary_10_4274_BMB_galenos_2025_69885
crossref_primary_10_1097_RLI_0000000000000197
crossref_primary_10_1007_s13139_016_0446_5
crossref_primary_10_1016_j_cpet_2023_04_006
crossref_primary_10_1053_j_ro_2018_08_007
crossref_primary_10_1097_MNM_0000000000000779
crossref_primary_10_3390_cancers14092103
crossref_primary_10_1080_10717544_2017_1399299
crossref_primary_10_1097_MD_0000000000015925
crossref_primary_10_1097_MNM_0000000000000661
crossref_primary_10_1007_s10549_014_3007_6
crossref_primary_10_1007_s00330_015_3630_6
crossref_primary_10_1097_MNM_0000000000001073
crossref_primary_10_3348_kjr_2015_16_2_219
crossref_primary_10_1016_j_soncn_2017_08_008
crossref_primary_10_1053_j_semnuclmed_2020_07_002
crossref_primary_10_1038_s41598_022_05166_2
crossref_primary_10_1186_1471_2407_13_538
crossref_primary_10_1093_jbi_wbae053
crossref_primary_10_1148_radiol_2021204677
crossref_primary_10_1186_s13014_020_01576_6
crossref_primary_10_1634_theoncologist_2014_0342
crossref_primary_10_3389_fmed_2016_00019
crossref_primary_10_23736_S1824_4785_19_03114_5
crossref_primary_10_1186_s40644_022_00468_0
crossref_primary_10_1097_RLU_0000000000000754
crossref_primary_10_1371_journal_pone_0120303
crossref_primary_10_1016_j_drudis_2021_07_025
crossref_primary_10_1259_bjr_20150268
crossref_primary_10_1053_j_semnuclmed_2024_01_007
crossref_primary_10_1016_j_ejca_2014_04_020
crossref_primary_10_1186_s13550_018_0359_7
crossref_primary_10_1007_s10549_016_4022_6
crossref_primary_10_1007_s10544_017_0173_4
crossref_primary_10_1016_S0959_8049_14_70068_1
crossref_primary_10_1016_j_cpet_2018_02_003
crossref_primary_10_1007_s40336_021_00426_z
crossref_primary_10_1016_j_cpet_2014_12_004
crossref_primary_10_1097_IOP_0000000000000115
crossref_primary_10_1007_s11307_017_1150_2
crossref_primary_10_1097_MNM_0000000000001726
crossref_primary_10_1007_s00259_014_2689_7
crossref_primary_10_1097_MNM_0000000000000910
crossref_primary_10_1186_s40658_020_00351_6
crossref_primary_10_1097_RUQ_0000000000000535
crossref_primary_10_1200_JCO_24_01945
crossref_primary_10_1016_j_cpet_2014_09_007
crossref_primary_10_1002_pro6_1245
crossref_primary_10_1016_j_ejrad_2015_03_026
crossref_primary_10_1007_s12149_021_01604_9
crossref_primary_10_1007_s12254_015_0210_z
crossref_primary_10_1245_s10434_015_4526_z
crossref_primary_10_1002_jmri_26298
crossref_primary_10_1007_s00259_018_4102_4
crossref_primary_10_1007_s00259_016_3430_5
crossref_primary_10_1007_s10549_014_2924_8
crossref_primary_10_1016_j_ejrad_2022_110334
crossref_primary_10_1097_RLU_0000000000003690
crossref_primary_10_1053_j_semnuclmed_2015_03_003
crossref_primary_10_1111_tbj_12570
crossref_primary_10_4329_wjr_v8_i8_743
crossref_primary_10_1016_j_breast_2024_103806
crossref_primary_10_1007_s00259_013_2553_1
crossref_primary_10_1200_JCO_2014_60_0353
crossref_primary_10_1007_s11307_018_1181_3
crossref_primary_10_1007_s11604_018_0785_5
crossref_primary_10_1007_s40336_022_00517_5
crossref_primary_10_1016_j_mednuc_2015_03_003
crossref_primary_10_1016_j_suronc_2021_101567
crossref_primary_10_1158_1078_0432_CCR_22_2720
crossref_primary_10_1007_s40336_019_00319_2
crossref_primary_10_4103_aort_aort_15_25
crossref_primary_10_1053_j_semnuclmed_2022_05_001
crossref_primary_10_1007_s13139_017_0485_6
crossref_primary_10_1007_s12149_019_01422_0
crossref_primary_10_1038_s43018_021_00223_7
crossref_primary_10_1002_acm2_13483
crossref_primary_10_1016_j_mednuc_2018_12_012
crossref_primary_10_1097_MD_0000000000000115
crossref_primary_10_1016_j_breast_2023_06_011
crossref_primary_10_1007_s00259_013_2600_y
crossref_primary_10_2217_fon_2019_0017
crossref_primary_10_1097_MNM_0000000000000217
crossref_primary_10_1097_MNM_0000000000000578
crossref_primary_10_1016_j_senol_2024_100629
crossref_primary_10_1016_j_cpet_2018_02_011
crossref_primary_10_1186_s40658_019_0256_9
crossref_primary_10_1016_j_mpsur_2019_01_011
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1148/radiol.12110853
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1527-1315
ExternalDocumentID 23220901
Genre Journal Article
Review
GroupedDBID ---
.55
.GJ
123
18M
1CY
1KJ
29P
2WC
34G
39C
4.4
53G
5RE
6NX
6PF
7FM
AAEJM
AAQQT
AAWTL
ABDPE
ABHFT
ABOCM
ACFQH
ACGFO
ACJAN
ADBBV
AENEX
AENYM
AFFNX
AFOSN
AJJEV
AJWWR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
F9R
GX1
H13
J5H
KO8
L7B
LMP
LSO
MJL
MV1
N4W
NPM
OK1
P2P
R.V
RKKAF
RXW
SJN
TAE
TR2
TRS
TWZ
W8F
WH7
WOQ
X7M
YQI
YQJ
ZGI
ZVN
ZXP
7X8
ID FETCH-LOGICAL-c363t-2ebe9c3c5425cc79faf25a6c1d78b2078c6e65caa6601f21224ad64667f3586a2
IEDL.DBID 7X8
ISICitedReferencesCount 199
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000314221700006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1527-1315
IngestDate Fri Sep 05 12:59:40 EDT 2025
Mon Jul 21 05:56:37 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c363t-2ebe9c3c5425cc79faf25a6c1d78b2078c6e65caa6601f21224ad64667f3586a2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 23220901
PQID 1283271612
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1283271612
pubmed_primary_23220901
PublicationCentury 2000
PublicationDate 2013-Feb
20130201
PublicationDateYYYYMMDD 2013-02-01
PublicationDate_xml – month: 02
  year: 2013
  text: 2013-Feb
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Radiology
PublicationTitleAlternate Radiology
PublicationYear 2013
SSID ssj0014587
Score 2.5093157
SecondaryResourceType review_article
Snippet In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 388
SubjectTerms Breast Neoplasms - diagnostic imaging
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Diagnosis, Differential
Female
Fluorodeoxyglucose F18 - pharmacokinetics
Humans
Multimodal Imaging
Neoplasm Recurrence, Local
Neoplasm Staging
Positron-Emission Tomography
Radiopharmaceuticals - pharmacokinetics
Sentinel Lymph Node Biopsy
Tomography, X-Ray Computed
Title Performance of FDG PET/CT in the clinical management of breast cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/23220901
https://www.proquest.com/docview/1283271612
Volume 266
WOSCitedRecordID wos000314221700006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ07T8MwEMdPQBFi4f0oLxmJ1Wpsx04yIVRaWFplKFK3yHFsqRIkfcHn55ymdEJCYskUS9H57PzOd74_wINVgQ2KIqS5ZjENnZVUS6lx4SXIIw7jljyuxSai4TAej5O0OXBbNGWV6z2x3qiLyvgz8g7zmjoI94w_TmfUq0b57GojobENLYEo4706Gm-yCKGsBfK8citlgsmmtQ9GAJ25LibVu--t4Mvvxe98Wf9n-of__cIjOGgIkzytXOIYtmx5AnuDJod-Cr10c1eAVI70n19I2ht1uiMyKQnyIFnfliQfP7Ux_sXc168vifED52fw1u-Nuq-0EVOgRiixpBxnKzHCSFykxkSJ045LrQwrcDo4goJRVkmjtcIQzXGfcNOFCpWKnJCx0vwcdsqqtJdAEkS2SLHcREqHwtq8SGxuLEfYYIEQvA33awNl6Kw-A6FLW30uso2J2nCxsnI2XXXVyBDteIB0cvWH0dewz2tZCl9WcgMth0vV3sKu-VpOFvO72gvwOUwH36YOulg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Performance+of+FDG+PET%2FCT+in+the+clinical+management+of+breast+cancer&rft.jtitle=Radiology&rft.au=Groheux%2C+David&rft.au=Espi%C3%A9%2C+Marc&rft.au=Giacchetti%2C+Sylvie&rft.au=Hindi%C3%A9%2C+Elif&rft.date=2013-02-01&rft.issn=1527-1315&rft.eissn=1527-1315&rft.volume=266&rft.issue=2&rft.spage=388&rft_id=info:doi/10.1148%2Fradiol.12110853&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-1315&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-1315&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-1315&client=summon